JO3566B1 - تركيبات عامل تمايز النمو 15 (gdf15) - Google Patents

تركيبات عامل تمايز النمو 15 (gdf15)

Info

Publication number
JO3566B1
JO3566B1 JOP/2014/0240A JOP20140240A JO3566B1 JO 3566 B1 JO3566 B1 JO 3566B1 JO P20140240 A JOP20140240 A JO P20140240A JO 3566 B1 JO3566 B1 JO 3566B1
Authority
JO
Jordan
Prior art keywords
constructs
gdf
differentiation factor
growth differentiation
gdf15
Prior art date
Application number
JOP/2014/0240A
Other languages
English (en)
Inventor
Z Sheng Jackie
Kannan Gunasekaran
Walker Kenneth
Wang Zhulun
Xiong Yumei
Shimamoto Grant
Mock Marissa
VENIANT?ELLISON Murielle
Eva Hamburger Agnes
Tang Jie
Zhang Yi
Min Xiaoshan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3566(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of JO3566B1 publication Critical patent/JO3566B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<span dir="RTL">يتم تقديم تركيبات تتضمن </span>GDF15<span dir="RTL">، ومطفرات منه. في نماذج مختلفة يمكن إستخدام التركيبات التي تتضمن </span>GDF15<span dir="RTL">، ومطفرات منه، للإستخدام في علاج أو تحسين إضطراب أيضي. في نماذج مختلفة يكون المرض أو الإضطراب الأيضي عبارة عن مرض السكري من النوع 2، السمنة، إضطراب نسبة الدهون بالدم، ارتفاع مستويات الجلوكوز بالدم، إرتفاع نسبة الأنسولين بالدم، وإعتلال الكلى السكري</span>
JOP/2014/0240A 2013-07-31 2014-08-03 تركيبات عامل تمايز النمو 15 (gdf15) JO3566B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31

Publications (1)

Publication Number Publication Date
JO3566B1 true JO3566B1 (ar) 2020-07-05

Family

ID=51358091

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0240A JO3566B1 (ar) 2013-07-31 2014-08-03 تركيبات عامل تمايز النمو 15 (gdf15)

Country Status (35)

Country Link
US (4) US9862752B2 (ar)
EP (2) EP3763734A1 (ar)
JP (5) JP6509852B2 (ar)
KR (3) KR20240000642A (ar)
CN (2) CN113527512A (ar)
AP (1) AP2016009011A0 (ar)
AR (1) AR097181A1 (ar)
AU (1) AU2014296107B2 (ar)
BR (1) BR112016002213A2 (ar)
CA (1) CA2918624C (ar)
CL (1) CL2016000249A1 (ar)
CR (1) CR20160097A (ar)
CY (1) CY1123836T1 (ar)
DK (1) DK3027642T3 (ar)
EA (2) EA037355B1 (ar)
ES (1) ES2828670T3 (ar)
HU (1) HUE050630T2 (ar)
IL (1) IL243749B (ar)
JO (1) JO3566B1 (ar)
LT (1) LT3027642T (ar)
MA (1) MA38873B1 (ar)
MX (2) MX369152B (ar)
NZ (2) NZ754961A (ar)
PE (1) PE20160189A1 (ar)
PH (1) PH12016500208B1 (ar)
PL (1) PL3027642T3 (ar)
PT (1) PT3027642T (ar)
SG (1) SG11201600713RA (ar)
SI (1) SI3027642T1 (ar)
TN (1) TN2016000035A1 (ar)
TW (1) TWI648401B (ar)
UA (1) UA116665C2 (ar)
UY (1) UY35686A (ar)
WO (1) WO2015017710A1 (ar)
ZA (1) ZA201600523B (ar)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3683228A3 (en) * 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
CN111163795A (zh) 2017-09-10 2020-05-15 诺沃挪第克公司 用于治疗肥胖症的mic-1和glp-1
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CR20200510A (es) 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
US20200017600A1 (en) * 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
EA202191105A1 (ru) * 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
JP7500619B2 (ja) 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作
MA56110A (fr) 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques à lieurs clivables de manière sélective
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
CA3161302A1 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
CA3159979A1 (en) * 2019-12-11 2021-06-17 Yeonchul Kim Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
CN115379850A (zh) * 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
WO2021168413A1 (en) * 2020-02-20 2021-08-26 Neutrolis, Inc. Basic domain-deleted dnase1-like 3 and uses thereof
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4237438A4 (en) 2020-10-27 2024-11-27 Beijing QL Biopharmaceutical Co., Ltd. GDF15 FUSION PROTEINS AND THEIR USE
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
US20240391971A1 (en) * 2021-08-24 2024-11-28 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
CA3233084A1 (en) * 2021-09-24 2023-03-30 Bionsystems Inc Fusion protein dimer comprising pd-1 and il-21, and use thereof
EP4476212A1 (en) 2022-02-10 2024-12-18 Novartis AG 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114835810B (zh) * 2022-03-31 2024-01-05 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用
WO2025024658A1 (en) * 2023-07-27 2025-01-30 Binacea Pharma, Inc. Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof
US20250163119A1 (en) 2023-11-17 2025-05-22 Eli Lilly And Company Compounds for the treatment of diabetes or obesity

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
HUP0105090A2 (hu) * 1999-01-07 2002-04-29 Lexigen Pharmaceuticals Corporation Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
AU2002250293B2 (en) 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
ES2383300T3 (es) * 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
WO2005113585A2 (en) * 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CN101356189A (zh) * 2005-11-10 2009-01-28 受体生物公司 肝细胞生长因子内含子融合蛋白
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2009141357A1 (en) 2008-05-20 2009-11-26 Roche Diagnostics Gmbh Gdf-15 as biomarker in type 1 diabetes
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
JP5444363B2 (ja) * 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP2679234A3 (en) * 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CN108387744A (zh) 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3415528B1 (en) * 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RS60499B1 (sr) * 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9248181B2 (en) * 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
KR101993714B1 (ko) * 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
EP3157947A1 (en) * 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
CR20160097A (es) 2016-07-29
US20160168213A1 (en) 2016-06-16
SI3027642T1 (sl) 2020-11-30
MX2016001164A (es) 2016-07-26
JP2023116723A (ja) 2023-08-22
MX2019012848A (es) 2019-11-28
TN2016000035A1 (en) 2017-07-05
AU2014296107B2 (en) 2018-07-26
PH12016500208A1 (en) 2016-04-25
EA037355B1 (ru) 2021-03-17
US20240368236A1 (en) 2024-11-07
DK3027642T3 (da) 2020-11-02
NZ754961A (en) 2022-04-29
US10894814B2 (en) 2021-01-19
EA202092386A1 (ru) 2021-04-30
JP2025024032A (ja) 2025-02-19
UY35686A (es) 2015-01-30
JP2016532690A (ja) 2016-10-20
ZA201600523B (en) 2024-10-30
KR20240000642A (ko) 2024-01-02
SG11201600713RA (en) 2016-02-26
US20210079051A1 (en) 2021-03-18
MA38873A1 (fr) 2017-09-29
AP2016009011A0 (en) 2016-01-31
CN105980400B (zh) 2021-05-07
IL243749B (en) 2018-06-28
CN113527512A (zh) 2021-10-22
TW201602345A (zh) 2016-01-16
PL3027642T3 (pl) 2021-01-11
CN105980400A (zh) 2016-09-28
BR112016002213A2 (pt) 2017-08-29
EA201690297A1 (ru) 2016-06-30
MX387211B (es) 2025-03-18
KR102616674B1 (ko) 2023-12-29
US9862752B2 (en) 2018-01-09
HK1225738A1 (en) 2017-09-15
JP6877478B2 (ja) 2021-05-26
JP6509852B2 (ja) 2019-05-08
EP3027642A1 (en) 2016-06-08
CA2918624A1 (en) 2015-02-05
AR097181A1 (es) 2016-02-24
EP3027642B1 (en) 2020-08-19
WO2015017710A1 (en) 2015-02-05
ES2828670T3 (es) 2021-05-27
KR20160038896A (ko) 2016-04-07
US20180079790A1 (en) 2018-03-22
PH12016500208B1 (en) 2016-04-25
CL2016000249A1 (es) 2016-07-22
AU2014296107A1 (en) 2016-02-04
UA116665C2 (uk) 2018-04-25
JP2021113219A (ja) 2021-08-05
JP2019178132A (ja) 2019-10-17
HUE050630T2 (hu) 2020-12-28
TWI648401B (zh) 2019-01-21
KR102376451B1 (ko) 2022-03-23
MA38873B1 (fr) 2018-11-30
MX369152B (es) 2019-10-30
IL243749A0 (en) 2016-04-21
PE20160189A1 (es) 2016-05-06
CY1123836T1 (el) 2022-03-24
EP3763734A1 (en) 2021-01-13
NZ717030A (en) 2022-04-29
CA2918624C (en) 2024-02-13
PT3027642T (pt) 2020-10-30
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12

Similar Documents

Publication Publication Date Title
ZA201600523B (en) Growth differentiation factor 15 (gdf-15) constructs
EP3683228A3 (en) Growth differentiation factor 15 (gdf-15) polypeptides
MX2013011726A (es) Metodo de tratamiento o mejoramiento de transtornos metabolicos usando el factor de diferenciacion de crecimiento 15 (gdf-15).
JOP20200202A1 (ar) اجسام مضادة بشرية لمستقبل الجلوكاجون
WO2013033452A3 (en) Fgf21 for use in treating type 1 diabetes
NZ596037A (en) Fgf21 mutants and uses thereof
IN2015DN00397A (ar)
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
WO2012174534A3 (en) Method of treating or ameliorating metabolic disorders using clec-2
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
PH12015502068A1 (en) Treatment of insulin resistance associated with prolonged physical inactivity
MX384123B (es) Nutrición infantil para el mejoramiento en la sensibilidad a la insulina más adelante en la vida.
WO2014014819A3 (en) Methods of treating glucose metabolism disorders
MX2017016141A (es) Producto a base de aguamiel de maguey para su uso en el control de la glucosa en personas con sindrome metabolico y/o diabetes.
TH168762A (th) สิ่งที่สร้างขึ้นเป็นโกรทดิฟเฟอเรนชิเอชันแฟคเตอร์ 15 (gdf-15)
UA79751U (ru) Способ прогнозирования течения заболевания у больных с первично-локализованной меланомой кожи
JO3333B1 (ar) استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه
UA82795U (ru) Способ оценки влияния электромагнитных излучений персональных компьютеров и мобильных телефонов на организм человека
MX2008001011A (es) Formulación auxiliar para el control de niveles altos de glucosa en sangre (hiperglicemia).